Skip to main content

QAAGZX

ETF
QAAGZX · UNKNOWN · 136 holdings

Quick Summary

Price History

Concentration Risk

46.63% Top-heavy
Low risk High risk

The top 10 holdings account for 46.63%. The biggest positions move the needle, but there's enough spread to cushion a single-stock blowup.

Top Holdings Today

Weighted by position size
LLY
▼ -0.44%
UNH
▲ 0.46%
ISRG
▼ -2.03%
SYK
▼ -0.41%
TMO
▼ -1.75%
ARGX
▼ -0.49%
VRTX
▼ -0.10%
BSX
▼ -0.45%
DHR
▼ -1.93%
ALNY
▼ -1.68%
Weighted avg. of top holdings ▼ -0.72%

Sector Allocation

Healthcare
79.56%
Manufacturing
0.46%

Top 10 Holdings

46.63% of fund
LLY Eli Lilly & Co
10.70%
UNH UnitedHealth Group Inc
7.09%
ISRG Intuitive Surgical Inc
4.94%
SYK Stryker Corp
4.45%
TMO Thermo Fisher Scientific Inc
3.96%
ARGX Argenx SE
3.54%
VRTX Vertex Pharmaceuticals Inc
3.26%
BSX Boston Scientific Corp
3.12%
DHR Danaher Corp
3.06%
ALNY Alnylam Pharmaceuticals Inc
2.52%
Other positions
9.32%

All Holdings (136)

Top 10: 46.63% of fund
# Ticker Name Weight Shares Market Value
1 LLY Eli Lilly & Co 10.70% 85,488 70.61 M
2 UNH UnitedHealth Group Inc 7.09% 89,328 46.79 M
3 ISRG Intuitive Surgical Inc 4.94% 65,792 32.58 M
4 SYK Stryker Corp 4.45% 78,853 29.35 M
5 TMO Thermo Fisher Scientific Inc 3.96% 52,560 26.15 M
6 ARGX Argenx SE 3.54% 39,472 23.36 M
7 VRTX Vertex Pharmaceuticals Inc 3.26% 44,425 21.54 M
8 BSX Boston Scientific Corp 3.12% 204,239 20.60 M
9 DHR Danaher Corp 3.06% 98,607 20.21 M
10 ALNY Alnylam Pharmaceuticals Inc 2.52% 61,636 16.64 M
Showing top 10 of 136 holdings · Listed: 90.68% · 9.32% in other positions

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) N/A
ROE N/A ROA N/A
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) N/A
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: N/A
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value N/A

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: N/A · EV/EBITDA: N/A
P/E Ratio N/A Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap N/A Enterprise Value N/A

Per Share

EPS: N/A · FCF/Share: N/A
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: N/A · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion N/A
SBC-Adj. FCF N/A Growth Momentum N/A

مقارنة الأقران

مقابل وسيط قطاع ETF (25157 نظير)
المقياس السهم وسيط القطاع
P/E
P/B
ROE %
Net Margin %
Rev Growth 5Y %
D/E